Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

[1] Agricultural and Environmental Diagnostics Market Size (2028) (businessresearchinsights.com)

[2] Food Safety Testing Market Size Will Attain 35.6 Billion by (globenewswire.com)

[3] Infectious Disease Diagnostic Market Statistics | Forecast – 2030 (alliedmarketresearch.com)

Press Releases

Subscribe

Valberedning utsedd i Diagonal Bio AB (publ) inför årsstämman 2025

Non-regulatory

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2024, har följande valberedning utsetts för Diagonal Bio AB (publ.) inför årsstämman den 20 maj, 2025.

Read more

Nomination Committee appointed for Diagonal Bio

Non-regulatory

Diagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.

Read more

Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro

Non-regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) will be participating in a partnered event with Svensk Galopp, at Jägersro on November 7, 2024. The Company’s diagnostic platform, LAMPlify®, will be introduced to a select group of invited trainers.

Read more

The last day of trading in warrants of series TO 1 is on the 24th of September 2024

Non-regulatory

The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) preferential rights issue of units that was carried out earlier in 2024. The exercise period runs until the 26th of September 2024.

Read more

The exercise period for warrants of series TO 1 commences today

Non-regulatory

Today is the first day for the exercise of Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) warrants of series TO 1 (“TO 1”) which were issued in connection with the preferential issue of units that the Company carried out earlier this year. The period lasts until June 26, 2024. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio for each TO 1 at a price of SEK 0,05 per share. Through full utilisation of TO 1, the Company will receive approximately SEK 2,25 million before issue costs. An information document is available on the respective websites of Diagonal Bio (www.diagonalbio.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

Read more

News

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Articles of association

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö